Stereotaxis (NYSEAMERICAN:STXS) Posts Earnings Results, Hits Estimates

Stereotaxis (NYSEAMERICAN:STXSGet Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06), MarketWatch Earnings reports. Stereotaxis had a negative net margin of 30.60% and a negative return on equity of 30.70%.

Stereotaxis stock traded down $0.08 on Wednesday, reaching $1.83. The company’s stock had a trading volume of 24,474 shares, compared to its average volume of 304,153. The firm has a market cap of $136.60 million, a P/E ratio of -11.63 and a beta of 1.74. Stereotaxis has a twelve month low of $1.88 and a twelve month high of $10.30.

Separately, Zacks Investment Research raised shares of Stereotaxis from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Stereotaxis presently has a consensus rating of “Buy” and an average target price of $10.20.

Several institutional investors have recently made changes to their positions in STXS. Jane Street Group LLC bought a new position in shares of Stereotaxis during the third quarter worth approximately $56,000. Schonfeld Strategic Advisors LLC bought a new stake in Stereotaxis in the 4th quarter valued at about $74,000. MetLife Investment Management LLC increased its holdings in Stereotaxis by 270.9% during the 4th quarter. MetLife Investment Management LLC now owns 19,595 shares of the company’s stock worth $121,000 after purchasing an additional 14,312 shares in the last quarter. Bank of America Corp DE increased its holdings in Stereotaxis by 117.7% during the 4th quarter. Bank of America Corp DE now owns 39,612 shares of the company’s stock worth $246,000 after purchasing an additional 21,413 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Stereotaxis in the 4th quarter worth approximately $281,000. Institutional investors own 56.84% of the company’s stock.

About Stereotaxis (Get Rating)

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.

Featured Articles

Earnings History for Stereotaxis (NYSEAMERICAN:STXS)

Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.